Which has better earnings & valuation, AVIR or LBRX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A

Is AVIR or LBRX more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% LB Pharmaceuticals N/A -25.92% -24.68%

Atea Pharmaceuticals (AVIR) Competitors

$5.36 -0.09 (-1.65%)

As of 08/28/2026 04:00 PM Eastern

Compare

AVIR vs. ETON, XERS, LBRX, INVA, and HROW

Should you buy Atea Pharmaceuticals stock or one of its competitors? Atea Pharmaceuticals's main competitors and comparable companies include Eton Pharmaceuticals (ETON), Xeris Biopharma (XERS), LB Pharmaceuticals (LBRX), Innoviva (INVA), and Harrow (HROW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Atea Pharmaceuticals compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Eton Pharmaceuticals has a net margin of 12.02% compared to Atea Pharmaceuticals' net margin of 0.00%. Eton Pharmaceuticals' return on equity of 40.13% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Eton Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$105.60M	16.18	-$4.60M	$0.38	157.32
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Eton Pharmaceuticals presently has a consensus target price of $67.50, indicating a potential upside of 12.91%. Atea Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 30.60%. Given Atea Pharmaceuticals' higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Eton Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

In the previous week, Eton Pharmaceuticals had 18 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 19 mentions for Eton Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.89 beat Eton Pharmaceuticals' score of 1.19 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Eton Pharmaceuticals	Positive
Atea Pharmaceuticals	Very Positive

Summary

Eton Pharmaceuticals beats Atea Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Xeris Biopharma has higher revenue and earnings than Atea Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$335.41M	4.61	$550K	-$0.11	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Xeris Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

In the previous week, Xeris Biopharma had 10 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 11 mentions for Xeris Biopharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.89 beat Xeris Biopharma's score of 1.53 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Xeris Biopharma	Very Positive
Atea Pharmaceuticals	Very Positive

Xeris Biopharma currently has a consensus price target of $12.00, indicating a potential upside of 41.51%. Atea Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 30.60%. Given Xeris Biopharma's higher probable upside, research analysts plainly believe Xeris Biopharma is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Atea Pharmaceuticals has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Xeris Biopharma beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Atea Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 30.60%. LB Pharmaceuticals has a consensus target price of $49.63, indicating a potential upside of 3.97%. Given Atea Pharmaceuticals' higher probable upside, research analysts clearly believe Atea Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, LB Pharmaceuticals had 14 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for LB Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.89 beat LB Pharmaceuticals' score of -0.02 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Very Positive
LB Pharmaceuticals	Neutral

LB Pharmaceuticals' return on equity of -25.92% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

Summary

Atea Pharmaceuticals and LB Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Innoviva?

Atea Pharmaceuticals (NASDAQ:AVIR) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Innoviva	$411.33M	3.68	$271.17M	$4.10	5.11

Innoviva has a net margin of 81.19% compared to Atea Pharmaceuticals' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Innoviva	81.19%	28.03%	20.19%

Atea Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

In the previous week, Innoviva had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 6 mentions for Innoviva and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.89 beat Innoviva's score of 1.29 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Very Positive
Innoviva	Positive

Atea Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 30.60%. Innoviva has a consensus target price of $34.75, indicating a potential upside of 65.71%. Given Innoviva's higher probable upside, analysts clearly believe Innoviva is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Innoviva	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Innoviva beats Atea Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Harrow?

Atea Pharmaceuticals (NASDAQ:AVIR) and Harrow (NASDAQ:HROW) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Atea Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Atea Pharmaceuticals currently has a consensus target price of $7.00, indicating a potential upside of 30.60%. Harrow has a consensus target price of $69.43, indicating a potential upside of 86.29%. Given Harrow's stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Harrow	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Atea Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -13.51%. Harrow's return on equity of -38.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Harrow	-13.51%	-38.00%	-3.37%

Harrow has higher revenue and earnings than Atea Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Harrow	$272.30M	5.13	-$5.14M	-$1.00	N/A

In the previous week, Harrow had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for Harrow and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.89 beat Harrow's score of 1.75 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Very Positive
Harrow	Very Positive

Summary

Harrow beats Atea Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$429.90M	$12.15B	$7.20B	$12.91B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-2.58	787.65	273.16	25.45
Price / Sales	N/A	795.08	634.73	93.93
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	2.10	11.97	12.98	6.14
Net Income	-$158.35M	$2.83B	$3.48B	$348.86M
7 Day Performance	-1.29%	0.39%	0.13%	-0.80%
1 Month Performance	13.08%	5.34%	7.08%	4.13%
1 Year Performance	59.52%	6.05%	24.67%	15.17%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	2.2284 of 5 stars	$5.36 -1.7%	$7.00 +30.6%	+59.5%	$429.90M	N/A	N/A	70	Gap Down
ETON Eton Pharmaceuticals	3.9185 of 5 stars	$63.43 +2.8%	$67.50 +6.4%	+245.3%	$1.61B	$79.95M	166.92	20	News Coverage Positive News Insider Trade
XERS Xeris Biopharma	4.0341 of 5 stars	$8.85 +3.9%	$10.80 +22.0%	+8.3%	$1.57B	$291.85M	N/A	290	Positive News
LBRX LB Pharmaceuticals	0.8903 of 5 stars	$48.77 +5.5%	$47.75 -2.1%	N/A	$1.54B	N/A	N/A	16	Analyst Revision
INVA Innoviva	3.3442 of 5 stars	$21.25 +1.4%	$34.75 +63.5%	+2.6%	$1.53B	$411.33M	5.18	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. ETON, XERS, LBRX, INVA, and HROW

How does Atea Pharmaceuticals compare to Eton Pharmaceuticals?

Summary

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Summary

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Summary

How does Atea Pharmaceuticals compare to Innoviva?

Summary

How does Atea Pharmaceuticals compare to Harrow?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. ETON, XERS, LBRX, INVA, and HROW

How does Atea Pharmaceuticals compare to Eton Pharmaceuticals?

Is ETON or AVIR more profitable?

Which has preferable earnings and valuation, ETON or AVIR?

Do institutionals & insiders believe in ETON or AVIR?

Do analysts recommend ETON or AVIR?

Which has more risk and volatility, ETON or AVIR?

Does the media favor ETON or AVIR?

Summary

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Which has stronger valuation and earnings, XERS or AVIR?

Which has more volatility and risk, XERS or AVIR?

Does the media favor XERS or AVIR?

Do analysts recommend XERS or AVIR?

Is XERS or AVIR more profitable?

Do insiders & institutionals believe in XERS or AVIR?

Summary

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Do analysts prefer AVIR or LBRX?

Do insiders & institutionals believe in AVIR or LBRX?

Does the media prefer AVIR or LBRX?

Is AVIR or LBRX more profitable?

Which has better earnings & valuation, AVIR or LBRX?

Summary

How does Atea Pharmaceuticals compare to Innoviva?

Do institutionals and insiders believe in AVIR or INVA?

Which has higher earnings and valuation, AVIR or INVA?

Is AVIR or INVA more profitable?

Which has more volatility and risk, AVIR or INVA?

Does the media refer more to AVIR or INVA?

Do analysts prefer AVIR or INVA?

Summary

How does Atea Pharmaceuticals compare to Harrow?

Which has more risk & volatility, AVIR or HROW?

Do institutionals and insiders believe in AVIR or HROW?

Do analysts recommend AVIR or HROW?

Is AVIR or HROW more profitable?

Which has stronger earnings and valuation, AVIR or HROW?

Does the media refer more to AVIR or HROW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools